

# Recombinant Human TNFSF14/LIGHT/HVEM-L/CD258 Protein

Catalog No.: RP01336 Recombinant

## **Sequence Information**

**Species Gene ID Swiss Prot** Human 8740 043557

**Tags** N-his

**Synonyms** 

TNFSF14;CD258;HVEML;LIGHT;LTg

#### **Product Information**

**Source** Purification HEK293 cells > 95% by SDS-

PAGE.

Calculated MW Observed MW 19.05 kDa 20-25 kDa

## **Endotoxin**

Please contact us for more information.

#### **Formulation**

Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4.

#### Reconstitution

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

# Contact

<b>a</b>		400-999-6126
$\bowtie$		cn.market@abclonal.com.cn
$\odot$	Τ	www.abclonal.com.cn

## **Background**

LIGHT, also known as TNFSF14 or CD258, is a newly identified member of the TNF superfamily (TNFSF14) that is expressed by activated T lymphocytes, monocytes, granulocytes, spleen cells, and immature dendritic cells. TNFSF14 / LIGHT / CD258 is a type II transmembrane protein that is known to bind 2 membrane-bound TNFSF signaling receptors: HVEM, which is predominantly expressed by T cells, and lymphotoxin  $\beta$  receptor (LT $\beta$ R), which is expressed by stromal cells and nonlymphoid hematopoietic cells. TNFSF14 / LIGHT / CD258 also binds to a soluble non-signaling receptor, decoy receptor 3 (DcR3), which can modulate the function of LIGHT in vivo. TNFSF14 / LIGHT / CD258 can also costimulate T cell responses via HVEM, which is constitutively expressed in most lymphocyte subpopulations, including CD4+and CD8+T cells. In addition, TNFSF14 / LIGHT / CD258 has been shown to suppress tumor formation in vivo and to induce tumor cell apoptosis via the up-regulation of intercellular adhesion molecule 1 and an increased lymphocyte adhesion to cancer cells. Thus, TNFSF14 / LIGHT / CD258 is being actively investigated as a possible basis for cancer treatment.

## **Basic Information**

#### **Description**

Recombinant Human TNFSF14/LIGHT/HVEM-L/CD258 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Asp74-Val240) of Human TNFSF14 (Accession  $\#NP_003798.2$ ) fused with a  $6\times$ His tag at the N-terminus.

## **Bio-Activity**

Measured by its binding ability in a functional ELISA. Immobilized Human TNFSF14 at 2  $\mu$ g/mL (100  $\mu$ L/well) can bind Mouse HVEM with a linear range of 0.02-0.89  $\mu$ g/mL.


#### **Storage**

Store at -20°C. Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt.


After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.

Avoid repeated freeze/thaw cycles.

# **Validation Data**



Recombinant Human TNFSF14/LIGHT/HVEM-L/CD258 Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 24kDa.



Immobilized Recombinant Human TNFSF14 at 2 µg/mL (100 µL/well) can bind Mouse HVEM with a linear range of 0.02-0.89 µg/mL.